MetaVia reports preclinical data showing obesity drug DA-1726 concentrates in adipose tissue
MTVA•Upcoming study readouts
Topline results from an ongoing 24-week dose-titration study are scheduled for release at 16 weeks in Q4 2026.
Topline results from the full 24-week readout are expected in Q1 2027.
Link to earlier Phase 1 results
Management tied the data to previously presented Phase 1 results showing meaningful waistline reductions, citing tolerability consistent with limited brain exposure.
Preclinical tissue-distribution results
MetaVia disclosed preclinical tissue-distribution results supporting its obesity drug candidate DA-1726, reinforcing its rationale for reducing waist size.
The findings point to preferential exposure in fat tissue with prolonged retention, consistent with the program’s once-weekly dosing profile.
